Ribozymes as Therapeutic Agents against Infectious Diseases

Wong, Bao Chi; Shahid, Umama; Tan, Hock Siew

doi:10.5772/intechopen.107141

Cited by 5 publications

(5 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methods for generating multivalent aptamers have also been developed to increase affinity of the aptamer constructs for the target up to 200-fold [131]. Aptamers could theoretically also be used to deliver ribozymes and DNAzymes, single stranded nucleic acid-based enzymes that have also been explored as therapeutics, including in antiviral and anticancer applications [132,133]. A potential drawback of this approach is that both aptamers and ribozymes/DNAzymes have extensive secondary structures that are essential for function, chimeras would have to be carefully designed to prevent disruption of those structures.…”

Section: Combinatorial Approachesmentioning

confidence: 99%

Therapeutic Applications of Aptamers

Santarpia,

Carnes

2024

Preprint

View full text Add to dashboard Cite

Affinity reagents, or target-binding molecules, are quite versatile and are major workhorses in molecular biology and medicine. Antibodies are the most famous and frequently used type and they have been used for a wide range of applications, including laboratory techniques, diagnostics, and therapeutics. However, antibodies are not the only available affinity reagents and they do have significant drawbacks, including laborious and costly production. Aptamers are one potential alternative that have a variety of unique advantages. They are single stranded DNA or RNA molecules that can be selected for binding to many targets including proteins, carbohydrates, and small molecules – for which antibodies typically have low affinity. There are also a variety of cost-effective methods for producing and modifying nucleic acids in vitro without cells, whereas antibodies typically require cells or even whole animals. While there are also significant drawbacks to using aptamers in therapeutic applications, including low in vivo stability, aptamers have had success in clinical trials for treating a variety of diseases and two aptamer-based drugs have gained FDA approval. Aptamer development is still ongoing, which could lead to additional applications of aptamer therapeutics, including antitoxins, and combinatorial approaches with nanoparticles and other nucleic acid therapeutics that could improve efficacy.

show abstract

Section: Combinatorial Approachesmentioning

confidence: 99%

Therapeutic Applications of Aptamers

Santarpia,

Carnes

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Methods for generating multivalent aptamers have also been developed to increase the affinity of the aptamer constructs of the target up to 200-fold [ 131 ]. Aptamers could theoretically also be used to deliver ribozymes and DNAzymes, single stranded nucleic acid-based enzymes that have also been explored as therapeutics, including in antiviral and anticancer applications [ 132 , 133 ]. A potential drawback of this approach is that both aptamers and ribozymes/DNAzymes have extensive secondary structures that are essential for their function, so chimeras would have to be carefully designed to prevent the disruption of those structures.…”

Section: Future Directionsmentioning

confidence: 99%

Therapeutic Applications of Aptamers

Santarpia,

Carnes

2024

IJMS

View full text Add to dashboard Cite

Affinity reagents, or target-binding molecules, are quite versatile and are major workhorses in molecular biology and medicine. Antibodies are the most famous and frequently used type and they have been used for a wide range of applications, including laboratory techniques, diagnostics, and therapeutics. However, antibodies are not the only available affinity reagents and they do have significant drawbacks, including laborious and costly production. Aptamers are one potential alternative that have a variety of unique advantages. They are single stranded DNA or RNA molecules that can be selected for binding to many targets including proteins, carbohydrates, and small molecules—for which antibodies typically have low affinity. There are also a variety of cost-effective methods for producing and modifying nucleic acids in vitro without cells, whereas antibodies typically require cells or even whole animals. While there are also significant drawbacks to using aptamers in therapeutic applications, including low in vivo stability, aptamers have had success in clinical trials for treating a variety of diseases and two aptamer-based drugs have gained FDA approval. Aptamer development is still ongoing, which could lead to additional applications of aptamer therapeutics, including antitoxins, and combinatorial approaches with nanoparticles and other nucleic acid therapeutics that could improve efficacy.

show abstract

“…Interestingly, some viral vector systems have been utilized to deliver and express ribozymes to cleave HIV RNA in humans. Some of these ribozyme-based antiviral tools are currently in various stages of human clinical trials [ 230 ]. Moreover, a recent innovation that could possibly provide additional solutions includes the generation of bacterial cells controlled by chemically synthesized genomes [ 231 ].…”

Section: Targeted Rna-cleaving Tools As Potential Antiviral Therapeuticsmentioning

confidence: 99%

Multidimensional futuristic approaches to address the pandemics beyond COVID-19

Kotwal,

Orekondey,

Saradadevi

et al. 2023

Heliyon

View full text Add to dashboard Cite

Ribozymes as Therapeutic Agents against Infectious Diseases

Cited by 5 publications

References 119 publications

Therapeutic Applications of Aptamers

Therapeutic Applications of Aptamers

Therapeutic Applications of Aptamers

Multidimensional futuristic approaches to address the pandemics beyond COVID-19

Contact Info

Product

Resources

About